journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/28089594/epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-sensitive-exon-19-insertion-and-exon-20-insertion-in-patients-with-advanced-non-small-cell-lung-cancer
#1
Yen-Ting Lin, Yi-Nan Liu, Shang-Gin Wu, James Chih-Hsin Yang, Jin-Yuan Shih
BACKGROUND: The clinical responsiveness to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients with exon 19 insertion and the specific exon 20 insertion (A763_Y764 insFQEA) are still not well known. MATERIALS AND METHODS: We analyzed cancer specimens taken from NSCLC patients for EGFR mutations using RNA reverse transcription polymerase chain reaction or direct DNA sequencing. The clinical course and responsiveness to an EGFR TKI in patients with EGFR exon 19 insertion or exon 20 insertion (A763_Y764 insFQEA) were recorded...
December 28, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28082049/evolution-and-increasing-complexity-of-the-therapeutic-landscape-in-advanced-non-small-cell-lung-cancer
#2
David R Gandara, Jonathan W Riess, Karen Kelly, Tianhong Li, Philip C Mack, Primo N Lara
The therapeutic landscape in advanced non-small-cell lung cancer (NSCLC) is rapidly changing. Never have so many changes of major importance occurred within so short a time. The present perspective describes this rapid evolution and resultant increasing complexity in the therapeutic decision-making process for the practicing oncologist.
December 24, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28089158/cardiac-dose-and-survival-after-stereotactic-body-radiotherapy-for-early-stage-non-small-cell-lung-cancer
#3
Amode R Tembhekar, Cari L Wright, Megan E Daly
INTRODUCTION: Recent analyses have identified cardiac dose as an important predictor of overall survival (OS) after chemoradiation for locally advanced non-small-cell lung cancer (NSCLC). However, the survival influence of the cardiac dose after stereotactic body radiotherapy (SBRT) is unknown. We performed a dose-volume histogram (DVH) analysis of patients treated with SBRT for early stage NSCLC to examine survival and cardiac toxicity. MATERIALS AND METHODS: We reviewed the medical records of patients who had undergone SBRT for early-stage NSCLC from June 2007 to June 2015 and documented the cardiac DVH parameters, including the maximum and mean dose and percentage of volume receiving >5, >10, >20, and >30 Gy (V5, V10, V20, and V30, respectively)...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28089157/genomic-profiling-of-circulating-tumor-dna-in-relapsed-egfr-mutated-lung-adenocarcinoma-reveals-an-acquired-fgfr3-tacc3-fusion
#4
Justin M Allen, Alexa B Schrock, Rachel L Erlich, Vincent A Miller, Philip J Stephens, Jeffrey S Ross, Sai-Hong Ignatius Ou, Siraj M Ali, Davood Vafai
No abstract text is available yet for this article.
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28087132/practice-patterns-of-thoracic-radiotherapy-for-extensive-stage-small-cell-lung-cancer-survey-of-us-academic-thoracic-radiation-oncologists
#5
Carl M Post, Vivek Verma, Timur Mitin, Charles B Simone
PURPOSE: Despite the recent CREST trial demonstrating a survival benefit to thoracic radiotherapy (TRT) for patients with extensive-stage small-cell lung cancer (ES-SCLC) with response to chemotherapy, as well as endorsement by current National Comprehensive Cancer Network guidelines, TRT may not be uniformly delivered in clinical practice across all circumstances. METHODS AND MATERIALS: We surveyed US academic thoracic radiation oncologists regarding their practice patterns for TRT and assessed conditions in which withholding TRT could be warranted...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28073681/association-of-cytoplasmic-cxcr4-with-loss-of-epithelial-marker-and-activation-of-erk1-2-and-akt-signaling-pathways-in-non-small-cell-lung%C3%A2-cancer
#6
Nabil F Saba, Yuxiang Wang, Hongpeng Fu, Lydia Koenig, Fadlo R Khuri, Dong M Shin, Zhuo Georgia Chen
OBJECTIVES: Compelling evidence demonstrates that CXC-chemokine receptor 4 (CXCR4) is involved in tumor invasion, angiogenesis, metastasis, and resistance to chemotherapy in addition to being one of the coreceptors for T-tropic human immunodeficiency virus entry into T cells. However, it remains controversial as to how to identify functionally activated CXCR4 in tumor biopsies, which would assist in determining which patients may benefit from potential CXCR4-targeted therapy. MATERIALS AND METHODS: Immunohistochemistry (IHC) staining on archival tissues of patients with non-small-cell lung cancer (NSCLC) was used to detect a panel of biomarkers, including phospho-ERK1/2, phospho-AKT, and E-cadherin, which are relevant to downstream signaling of CXCR4 and epithelial to mesenchymal transition (EMT)...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28065465/a-multicenter-double-blind-phase-ii-study-of-metformin-with-gefitinib-as-first-line-therapy-of-locally-advanced-non-small-cell-lung-cancer
#7
Kun-Lin Li, Li Li, Peng Zhang, Jun Kang, Yu-Bo Wang, Heng-Yi Chen, Yong He
We present the rationale and study design of the CGMT (combined gefitinib and metformin therapy) trial (www.ClinicalTrials.gov Identifier: NCT01864681), which is aimed at treating locally advanced non-small-cell lung cancer. The CGMT trial is a multicenter, phase II randomized, double-blinded, and placebo-controlled study, which is designed to evaluate the safety and efficacy of metformin in combination with gefitinib as first-line therapy in patients presenting with stage IIIb-IV non-small-cell lung cancer expressing the epidermal growth factor receptor mutant...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28038981/high-frequency-of-programmed-death-ligand-1%C3%A2-expression-in-emphysematous-bullae-associated-lung-adenocarcinomas
#8
Gouji Toyokawa, Kazuki Takada, Tatsuro Okamoto, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Shinkichi Takamori, Takaki Akamine, Masakazu Katsura, Fumihiro Shoji, Yoshinao Oda, Yoshihiko Maehara
OBJECTIVE: Emphysematous bullae (EB) are known to be associated with a high incidence of lung cancer; however, the reason for this has yet to be elucidated. The objective of the present study was to clarify the prevalence of programmed death-ligand-1 (PD-L1) expression in EB-associated lung adenocarcinomas. PATIENTS AND METHODS: A total of 369 patients with resected lung adenocarcinoma whose preoperative computed tomography findings were available for the examination of EB were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and EB-related adenocarcinomas...
December 9, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28040379/stereotactic-body-radiotherapy-for-large-5-cm-non-small-cell-lung-cancer
#9
Justin Peterson, Christian Niles, Ashish Patel, Ziad Boujaoude, Wissam Abouzgheib, Ben Goldsmith, Sucha Asbell, Qianyi Xu, Polina Khrizman, Gregory J Kubicek
BACKGROUND: Stereotactic body radiotherapy (SBRT) is a well-established treatment option for early stage non-small-cell lung cancer (NSCLC) tumors < 5 cm. There is limited information on tumors > 5 cm. PATIENTS AND METHODS: We performed retrospective data collection of patients enrolled onto a prospective SBRT registry study. Eligible patients for this study had node-negative NSCLC measuring > 5 cm in any dimension. Data from 41 patients were analyzed...
December 8, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28065466/sequential-use-of-anaplastic-lymphoma-kinase-inhibitors-in-japanese-patients-with-alk-rearranged-non-small-cell-lung-cancer-a%C3%A2-retrospective-analysis
#10
Tetsuhiko Asao, Yutaka Fujiwara, Kota Itahashi, Shinsuke Kitahara, Yasushi Goto, Hidehito Horinouchi, Shintaro Kanda, Hiroshi Nokihara, Noboru Yamamoto, Kazuhisa Takahashi, Yuichiro Ohe
BACKGROUND: Second-generation anaplastic lymphoma kinase (ALK) inhibitors, such as alectinib and ceritinib, have recently been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). An optimal strategy for using 2 or more ALK inhibitors has not been established. We sought to investigate the clinical impact of sequential use of ALK inhibitors on these tumors in clinical practice. PATIENTS AND METHODS: Patients with ALK-rearranged NSCLC treated from May 2010 to January 2016 at the National Cancer Center Hospital were identified, and their outcomes were evaluated retrospectively...
December 7, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28043773/pulmonary-sarcomatoid-carcinoma-an-analysis-of-the-national-cancer-data-base
#11
Conor E Steuer, Madhusmita Behera, Yuan Liu, Chao Fu, Theresa W Gillespie, Nabil F Saba, Dong M Shin, Rathi N Pillai, Suchita Pakkala, Taofeek K Owonikoko, Fadlo R Khuri, Suresh S Ramalingam
INTRODUCTION: Pulmonary sarcomatoid carcinoma (PSC) is a grouping of 5 rare non-small-cell lung cancer (NSCLC) subtypes. We studied the clinical characteristics and outcomes of PSC utilizing the National Cancer Data Base (NCDB), an oncology outcomes database. METHODS: The NCDB lung cancer database was queried from 1998 to 2011 for PSC using ICD-O-3 codes. Data were extracted for patient demographics, tumor pathology, treatment, and outcomes. Overall survival (OS) data were available for patients diagnosed from 1998 to 2006 and comorbidity data from 2003 to 2011...
December 7, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28038980/epidermal-growth-factor-receptor-mutational-testing-and-erlotinib-treatment-among-veterans-diagnosed-with-lung-cancer-in-the-united-states-department-of-veterans-affairs
#12
Julie A Lynch, Brygida Berse, Danielle Chun, Donna Rivera, Kelly K Filipski, Scott Kulich, Benjamin Viernes, Scott L DuVall, Michael J Kelley
INTRODUCTION: We examined mutational testing of the epidermal growth factor gene (EGFR) and erlotinib treatment among veterans diagnosed with non-small-cell lung cancer in the United States Department of Veterans Affairs (VA). Our objectives were to identify the prevalence of clinically actionable EGFR mutations, to determine whether testing and treatment were guideline concordant, to evaluate the impact of testing and treatment on survival, and to estimate the rate of testing. PATIENTS AND METHODS: Test results were linked to electronic health records from VA Corporate Data Warehouse and the VA Central Cancer Registry...
December 7, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28089159/immunohistochemistry-for-egfr-mutation-detection-in-non-small-cell-lung-cancer
#13
Nina Turnšek Hitij, Izidor Kern, Aleksander Sadikov, Lea Knez, Karmen Stanič, Matjaž Zwitter, Tanja Cufer
INTRODUCTION: The sensitivity and specificity of immunohistochemistry (IHC) was compared with the standard polymerase chain reaction (PCR)-based method for detecting common activating epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC). Additionally, we evaluated predictive value of IHC EGFR mutation-positive status for EGFR tyrosine kinase inhibitor (TKI) treatment outcome and estimated cost-effectiveness for the upfront IHC testing. METHODS: The trial included 79 consecutive EGFR mutation-positive and 29 EGFR mutation-negative NSCLC cases diagnosed with reflex PCR-based testing...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28073680/rationale-and-design-of-pemvitastart-an-open-label-randomized-trial-comparing-simultaneous-versus-standard-initiation-of-vitamin-b12-and-folate-supplementation-in-nonsquamous-non-small-cell-lung-cancer-patients-undergoing-first-line-pemetrexed-based-chemotherapy
#14
Milind Baldi, Digambar Behera, Jyotdeep Kaur, Rakesh Kapoor, Navneet Singh
Pemetrexed is the preferred chemotherapeutic drug for nonsquamous, non-small-cell lung cancer patients whenever the predictive molecular biomarkers for targeted therapy have either not been assessed or are absent. As per manufacturers' instructions, supplementation with folic acid (FA; folate) at a dose of 350 to 1000 μg daily should be started seven days before the first dose of pemetrexed-based chemotherapy and continued during therapy and for 21 days after therapy cessation. Vitamin B12 injections (1000 μg intramuscularly) should also be started one week before the first dose of chemotherapy...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28065467/lung-adenocarcinoma-with-muc4-expression-is-associated-with-smoking-status-her2-protein-expression-and-poor-prognosis-clinicopathologic-analysis-of-338-cases
#15
Mariyo Rokutan-Kurata, Akihiko Yoshizawa, Shinji Sumiyoshi, Makoto Sonobe, Toshi Menju, Masanobu Momose, Mizuki Koyama, Shohei Shigeto, Masakazu Fujimoto, Meng Zhang, Satoshi Morita, Hiroshi Date, Hironori Haga
BACKGROUND: MUC4 is a transmembrane glycoprotein that plays a role in the cell growth signaling pathway and has been studied in various organ malignancies. This study aimed to analyze MUC4 expression in resected lung adenocarcinomas (ADCs) to define the clinicopathologic characteristics of MUC4-positive cancers. PATIENTS AND METHODS: Immunohistochemical MUC4 analysis was performed using tissue microarray slides containing 338 lung ADCs. Associations between MUC4 expression and the following clinicopathologic parameters were evaluated: sex; age; smoking status; tumor stage; tumor grade; lymphovascular invasion; pleural invasion; TTF-1 and HNF4α expression; EGFR, KRAS, BRAF, and HER2 mutation status; and ALK and ROS1 fusion status...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28063799/phase-ii-trial-of-dose-dense-pemetrexed-gemcitabine-and-bevacizumab-in-patients-with-advanced-non-small-cell-lung-cancer
#16
Bryan J Schneider, Gregory P Kalemkerian, Shirish M Gadgeel, Manuel Valdivieso, Deborah M Hackstock, Wei Chen, Lance K Heilbrun, John C Ruckdeschel, Antoinette J Wozniak
INTRODUCTION: Platinum-based chemotherapy is standard for untreated, advanced non-small-cell lung cancer (NSCLC). We investigated the activity and tolerability of the novel combination of dose-dense pemetrexed, gemcitabine, and bevacizumab in patients with advanced NSCLC. METHODS: This multicenter phase II trial evaluated the safety and efficacy of the combination of pemetrexed (400 mg/m(2)), gemcitabine (1200 mg/m(2)), and bevacizumab (10 mg/kg), given every 14 days in patients with untreated, advanced NSCLC...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28057436/comparison-of-clinically-relevant-mutation-profiles-between-preoperative-biopsy-and-corresponding-surgically-resected-specimens-in-japanese-patients-with-non-small-cell-lung-cancer-by-amplicon-based-massively-parallel-sequencing
#17
Mitsuhiro Isaka, Masakuni Serizawa, Hirotsugu Kenmotsu, Yasuhiro Koh, Shoji Takahashi, Tomohiro Maniwa, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Masahiro Endo, Masato Abe, Isamu Hayashi, Takashi Nakajima, Nobuyuki Yamamoto, Toshiaki Takahashi, Yasuhisa Ohde
BACKGROUND: Amplicon-based massively parallel sequencing (MPS) is an effective platform for identifying clinically actionable mutations across many genes in limited amounts of tissue. Most lung cancers are diagnosed and staged using small tissue samples obtained by transbronchial biopsy (TBB). To determine whether the mutations in TBB specimens detected by amplicon-based MPS reflect those present in the tumors, we compared the mutational profiles of preoperative TBB specimens and corresponding surgically resected specimens...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28027850/nine-year-experience-prophylactic-cranial-irradiation-in-extensive-disease-small-cell-lung%C3%A2-cancer
#18
Denise Bernhardt, Sebastian Adeberg, Farastuk Bozorgmehr, Nils Opfermann, Juliane Hoerner-Rieber, Michael C Repka, Jutta Kappes, Michael Thomas, Helge Bischoff, Felix Herth, Claus Peter Heußel, Jürgen Debus, Martin Steins, Stefan Rieken
BACKGROUND: In 2007, the European Organization for Research and Treatment of Cancer (EORTC) study (ClinicalTrials.gov identifier, NCT00016211) demonstrated a beneficial effect on overall survival (OS) with the use of prophylactic cranial irradiation (PCI) for extensive disease (ED) small-cell lung cancer (SCLC). Nevertheless, debate is ongoing regarding the role of PCI, because the patients in that trial did not undergo magnetic resonance imaging (MRI) of the brain before treatment. Also, a recent Japanese randomized trial showed a detrimental effect of PCI on OS in patients with negative pretreatment brain MRI findings...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28024928/molecular-profiling-and-survival-of-completely-resected-primary-pulmonary-neuroendocrine-carcinoma
#19
Guangyuan Lou, Xinmin Yu, Zhengbo Song
BACKGROUND: Currently, molecular profiles and prognosis of primary pulmonary neuroendocrine carcinoma (PNC) are poorly elucidated. The present study was designed to evaluate genomic abnormalities and survival in patients with primary PNC. METHODS: Completely resected PNC samples were collected from Zhejiang Cancer Hospital during the period of 2008 to 2015. Nine driver genes, including 6 mutations (EGFR, KRAS, NRAS, PIK3CA, BRAF, and HER2) and 3 fusions (ALK, ROS1, and RET), were evaluated by reverse transcription-polymerase chain reaction (RT-PCR)...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27993482/bevacizumab-plus-pemetrexed-versus-pemetrexed-alone-as-maintenance-therapy-for-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-update-from-the-swiss-group-for-clinical-cancer-research-sakk-19-09-trial
#20
Oliver Gautschi, Sacha I Rothschild, Qiyu Li, Klazien Matter-Walstra, Alfred Zippelius, Daniel C Betticher, Martin Früh, Rolf A Stahel, Richard Cathomas, Daniel Rauch, Miklos Pless, Solange Peters, Patrizia Froesch, Thilo Zander, Martina Schneider, Christine Biaggi, Nicolas Mach, Adrian F Ochsenbein
BACKGROUND: Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous non-small-cell lung cancer. It is currently unknown whether bevacizumab plus pemetrexed is superior to pemetrexed alone. PATIENTS AND METHODS: We conducted a nonrandomized phase II trial with 2 sequential cohorts. In the first cohort, 77 patients were treated with 4 cycles of cisplatin, bevacizumab, and pemetrexed every 3 weeks, followed by bevacizumab plus pemetrexed maintenance until progression...
November 23, 2016: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"